{"id":"drug-treatment-with-cymbalta","rwe":[],"tags":[],"safety":{"boxedWarnings":["Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults"],"drugInteractions":["Monoamine oxidase inhibitors (MAOIs)","Serotonergic drugs (e.g., SSRIs, triptans)","Drugs that affect serotonin or norepinephrine metabolism"],"commonSideEffects":[{"effect":"Nausea","drugRate":"23%","severity":"Moderate"},{"effect":"Dizziness","drugRate":"16%","severity":"Mild"},{"effect":"Fatigue","drugRate":"12%","severity":"Mild"},{"effect":"Dry mouth","drugRate":"10%","severity":"Mild"},{"effect":"Constipation","drugRate":"9%","severity":"Mild"},{"effect":"Somnolence","drugRate":"8%","severity":"Mild"},{"effect":"Decreased appetite","drugRate":"7%","severity":"Mild"},{"effect":"Sweating","drugRate":"6%","severity":"Mild"},{"effect":"Headache","drugRate":"5%","severity":"Mild"}],"contraindications":["Concomitant use of monoamine oxidase inhibitors (MAOIs)","Uncontrolled narrow-angle glaucoma"],"specialPopulations":{"Elderly":"Use with caution; start at lower doses","Lactation":"Use with caution; benefits should outweigh risks","Pregnancy":"Category C: Risk cannot be ruled out","Renal impairment":"Dose adjustment may be necessary","Hepatic impairment":"Dose adjustment may be necessary"}},"trials":[],"_chembl":{"chemblId":"CHEMBL157030","moleculeType":"Small molecule","molecularWeight":"883.99"},"aliases":["Duloxetine Hydrochloride"],"patents":[{"number":"US6127396","issueDate":"2000-10-03","description":"Method of treating depression using duloxetine","expirationDate":"2020-10-03"},{"number":"US6326381","issueDate":"2001-12-04","description":"Method of treating pain using duloxetine","expirationDate":"2021-12-04"}],"pricing":[],"_fixedAt":"2026-03-30T16:09:14.842047","offLabel":[],"timeline":[{"date":"2004-08-01","type":"Approval","milestone":"FDA approval for major depressive disorder","regulator":"FDA"},{"date":"2004-10-01","type":"Launch","milestone":"Launch in the United States","regulator":"FDA"},{"date":"2008-09-01","type":"Approval","milestone":"FDA approval for generalized anxiety disorder","regulator":"FDA"},{"date":"2009-03-01","type":"Approval","milestone":"FDA approval for diabetic peripheral neuropathic pain","regulator":"FDA"},{"date":"2010-06-01","type":"Approval","milestone":"FDA approval for fibromyalgia","regulator":"FDA"},{"date":"2011-01-01","type":"Approval","milestone":"FDA approval for chronic musculoskeletal pain","regulator":"FDA"}],"_dailymed":null,"aiSummary":"Cymbalta, also known as duloxetine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) primarily used to treat depression and anxiety disorders. It is also prescribed for chronic pain conditions such as diabetic neuropathy and fibromyalgia. Despite its effectiveness, Cymbalta has several side effects, including nausea, dizziness, and fatigue. The drug is not approved by the FDA for use at Jefferson Clinic, P.C., which may affect its prescription practices. Patients should be monitored closely for potential adverse reactions and interactions with other medications.","ecosystem":[],"mechanism":{"target":"Serotonin and norepinephrine transporters","novelty":"Cymbalta was one of the first SNRIs to be developed and has been widely studied for its efficacy in treating various psychiatric and pain conditions.","modality":"Oral capsule","drugClass":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","explanation":"Cymbalta works by blocking the reabsorption (reuptake) of serotonin and norepinephrine into neurons, thereby increasing their availability in the synaptic cleft.","oneSentence":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain.","technicalDetail":"Duloxetine selectively inhibits the reuptake of serotonin and norepinephrine by interacting with the presynaptic serotonin and norepinephrine transporters."},"_scrapedAt":"2026-03-28T00:35:38.124Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"3%","launchDate":"2004","annualCostUS":"$300 - $400 per month","currentRevenue":"$4.5 billion","patientPopulation":"Approximately 10 million patients worldwide","peakSalesEstimate":"$5.0 billion"},"references":[],"biosimilars":[],"competitors":["Effexor XR (venlafaxine)","Pristiq (desvenlafaxine)","Savella (milnacipran)"],"indications":{"approved":["Major depressive disorder","Generalized anxiety disorder","Diabetic peripheral neuropathic pain","Fibromyalgia","Chronic musculoskeletal pain"],"offLabel":["Chronic low back pain","Osteoarthritis pain"],"pipeline":[]},"_fixedFields":["pubmed(59)"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07439536","phase":"PHASE4","title":"Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2024-07-01","conditions":"Liver Cirrhosis With Diabetes","enrollment":64},{"nctId":"NCT06997198","phase":"PHASE4","title":"Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities","status":"NOT_YET_RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2026-03-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":25},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":"Healthy, Major Depressive Disorder (MDD)","enrollment":204},{"nctId":"NCT06837857","phase":"PHASE2","title":"Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-16","conditions":"Pain, Chronic","enrollment":200},{"nctId":"NCT07203339","phase":"NA","title":"Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine: Non-inferiority Clinical Trial (FIBROSTIM)","status":"RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2025-09-30","conditions":"Fibromyalgia (FM), tDCS, Duloxetine","enrollment":610},{"nctId":"NCT06672419","phase":"NA","title":"Effectiveness of AI-Guided Exercise and Pain Neuroscience Education for Fibromyalgia (FIBROIA)","status":"NOT_YET_RECRUITING","sponsor":"Instituto Neurociencia Del Dolor","startDate":"2026-02-01","conditions":"Fibromyalgia, Fibromyalgia Syndrome","enrollment":50},{"nctId":"NCT07296770","phase":"PHASE3","title":"An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-05-01","conditions":"Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery","enrollment":126},{"nctId":"NCT04870957","phase":"PHASE4","title":"The Back Pain Consortium Research Program Study","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2021-06-09","conditions":"Chronic Low-back Pain","enrollment":494},{"nctId":"NCT05086393","phase":"PHASE4","title":"Duloxetine RCT on Postop TKA Outcomes","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2021-11-01","conditions":"Pain, Postoperative, Total Knee Arthroplasty","enrollment":241},{"nctId":"NCT04395001","phase":"PHASE4","title":"Pain Response Evaluation of a Combined Intervention to Cope Effectively","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-02-24","conditions":"Chronic Pain","enrollment":280},{"nctId":"NCT04111627","phase":"PHASE2","title":"Exercise Plus Duloxetine for Knee Osteoarthritis","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2021-10-07","conditions":"Knee Osteoarthritis, Depression","enrollment":43},{"nctId":"NCT07161492","phase":"NA","title":"A Study on Functional Connectome and rTMS Intervention of Cognitive Flexibility Impairment in Patients With Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2025-09","conditions":"Depressive Disorder, Major, Cognitive Impairment","enrollment":182},{"nctId":"NCT05396014","phase":"PHASE4","title":"The BEST Trial: Biomarkers for Evaluating Spine Treatments","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-09-12","conditions":"Chronic Low-back Pain","enrollment":1014},{"nctId":"NCT05611749","phase":"PHASE2","title":"Duloxetine Impact on Postoperative Pain Control and Outcomes","status":"TERMINATED","sponsor":"Scripps Health","startDate":"2023-05-30","conditions":"Acute Post-operative Pain, Chronic Post Operative Pain, Narcotic Use","enrollment":17},{"nctId":"NCT02417064","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-10","conditions":"Treatment-resistant Depression","enrollment":346},{"nctId":"NCT03434041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-25","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":252},{"nctId":"NCT02493868","phase":"PHASE3","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":719},{"nctId":"NCT02418585","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-07","conditions":"Treatment-resistant Depression","enrollment":236},{"nctId":"NCT02497287","phase":"PHASE3","title":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-30","conditions":"Treatment-resistant Depression","enrollment":802},{"nctId":"NCT02422186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-20","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":139},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT03852160","phase":"PHASE3","title":"A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"Janssen-Cilag International NV","startDate":"2019-12-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":""},{"nctId":"NCT04504812","phase":"PHASE3","title":"A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2021-02-01","conditions":"Knee Osteoarthritis","enrollment":1937},{"nctId":"NCT05786599","phase":"PHASE2, PHASE3","title":"Methadone to Treat Painful Chemotherapy Induced Peripheral Neuropathy","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2025-03-21","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":50},{"nctId":"NCT06407401","phase":"PHASE3","title":"Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2024-12","conditions":"ER+ Breast Cancer, HER2-negative Breast Cancer, Breast Cancer Stage I","enrollment":399},{"nctId":"NCT06107829","phase":"PHASE4","title":"Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities","status":"WITHDRAWN","sponsor":"Stephen Ruedrich","startDate":"2025-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":""},{"nctId":"NCT03797560","phase":"NA","title":"Comparison of Ba-Duan-Jin and Pregabalin in Patients with Fibromyalgia","status":"COMPLETED","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-03-22","conditions":"Fibromyalgia","enrollment":104},{"nctId":"NCT03890133","phase":"NA","title":"Exploration the Mechanism of Ba-Duan-Jin Therapy in the Management of Fibromyalgia","status":"COMPLETED","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-04-01","conditions":"Fibromyalgia","enrollment":60},{"nctId":"NCT06551051","phase":"PHASE2","title":"ADC-induced Neurotoxicity Treated With Duloxetine","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-08-06","conditions":"Solid Tumour","enrollment":37},{"nctId":"NCT00200902","phase":"PHASE4","title":"Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2005-08","conditions":"Depression","enrollment":88},{"nctId":"NCT03325959","phase":"NA","title":"Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome","status":"COMPLETED","sponsor":"Assaf-Harofeh Medical Center","startDate":"2017-03-01","conditions":"Fibromyalgia, Hyperbaric Oxygen","enrollment":76},{"nctId":"NCT04316702","phase":"NA","title":"Hyperbaric Oxygen Therapy Compared to Pharmaceutical in Fibromyalgia With Emotional Trauma","status":"COMPLETED","sponsor":"Assaf-Harofeh Medical Center","startDate":"2020-03-01","conditions":"Fibromyalgia, Emotional Trauma","enrollment":48},{"nctId":"NCT05256342","phase":"NA","title":"Biomarkers for Prediction of Analgesic Efficacy in Knee OA.","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2021-12-30","conditions":"Knee, Osteoarthritis (OA), Biomarkers for Prediction of OA Treatment Efficacy","enrollment":17},{"nctId":"NCT04478526","phase":"NA","title":"Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions","status":"COMPLETED","sponsor":"Dr. Nazanin Alavi","startDate":"2020-04-29","conditions":"Generalized Anxiety Disorder","enrollment":115},{"nctId":"NCT06301061","phase":"NA","title":"Focal Microvibration and Chronic Lumbosacral Radicular Pain","status":"NOT_YET_RECRUITING","sponsor":"Federico II University","startDate":"2024-04-01","conditions":"Pain, Chronic, Lumbosacral Radiculopathy, Radicular; Neuropathic","enrollment":150},{"nctId":"NCT06232473","phase":"PHASE4","title":"Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic Disorder","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2024-01-01","conditions":"Functional Disorder","enrollment":424},{"nctId":"NCT04437485","phase":"PHASE2","title":"eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-10-14","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":46},{"nctId":"NCT02458690","phase":"PHASE2","title":"eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-07","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":216},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT06025474","phase":"PHASE3","title":"Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2023-01-01","conditions":"Burning Mouth Syndrome","enrollment":203},{"nctId":"NCT05952713","phase":"","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","status":"COMPLETED","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2022-10-01","conditions":"Major Depressive Disorder","enrollment":73336},{"nctId":"NCT03534063","phase":"NA","title":"Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-06-07","conditions":"Pain, Postoperative","enrollment":260},{"nctId":"NCT05930912","phase":"","title":"Psychiatric Orders in Psychoanalytic Treatment of ASD","status":"UNKNOWN","sponsor":"Yang I. Pachankis, PhD","startDate":"2023-06-01","conditions":"PTSD, Autism Spectrum Disorder High-Functioning, OCD","enrollment":1},{"nctId":"NCT04653337","phase":"PHASE2","title":"Neuroimaging Guided and Robot-assisted rTMS for Suicidal Ideation of Depression","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2020-09-28","conditions":"Suicidal Ideation, Depression","enrollment":56},{"nctId":"NCT04748276","phase":"","title":"Tracking Response to Antidepressants in Advance of Investigational Trials","status":"UNKNOWN","sponsor":"Adams Clinical","startDate":"2019-01-02","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT05486026","phase":"PHASE2","title":"Efficacy of Duloxetine Compared to NSIADs in Osteoarthritis of Knee","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2022-08-20","conditions":"Osteo Arthritis Knee","enrollment":200},{"nctId":"NCT04732455","phase":"NA","title":"Lidocaine Versus Duloxetine for the Prevention of Taxane-Induced Peripheral Neuropathy In Breast Cancer Patients","status":"COMPLETED","sponsor":"Gamal Mohamed Taha Abouelmagd","startDate":"2021-01-15","conditions":"Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Breast Cancer","enrollment":60},{"nctId":"NCT04697693","phase":"PHASE4","title":"Antidepressant Response in Older Adults With Comorbid PTSD and MDD","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-03-03","conditions":"Post Traumatic Stress Disorder, Major Depressive Disorder","enrollment":1},{"nctId":"NCT05254652","phase":"NA","title":"The Clinical Effect of Pregabalin on Neuropathic Pain in Central Sensitized Patients After Total Knee Arthroplasty","status":"UNKNOWN","sponsor":"The Catholic University of Korea","startDate":"2022-05","conditions":"Osteoarthritis","enrollment":90},{"nctId":"NCT02655354","phase":"NA","title":"A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-10","conditions":"Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders","enrollment":635},{"nctId":"NCT01436175","phase":"PHASE3","title":"SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study","status":"TERMINATED","sponsor":"Shire","startDate":"2012-02-27","conditions":"Major Depressive Disorder","enrollment":1570},{"nctId":"NCT01436162","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-19","conditions":"Major Depressive Disorder","enrollment":1105},{"nctId":"NCT00564278","phase":"NA","title":"Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-02","conditions":"Depression","enrollment":217},{"nctId":"NCT01973283","phase":"PHASE4","title":"Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-02-19","conditions":"Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder, NOS","enrollment":100},{"nctId":"NCT00742573","phase":"PHASE2","title":"Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-08","conditions":"Major Depressive Disorder","enrollment":170},{"nctId":"NCT02869035","phase":"PHASE1","title":"Treatment Outcome in Major Depressive Disorder","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2016-08","conditions":"Major Depressive Disorder","enrollment":100},{"nctId":"NCT01838876","phase":"PHASE3","title":"Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2013-04-29","conditions":"Major Depressive Disorder","enrollment":442},{"nctId":"NCT01057329","phase":"","title":"Therapeutic Drug Monitoring in Child and Adolescent Psychiatry","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2010-01","conditions":"Depression, Anorexia Nervosa, ADHD","enrollment":200},{"nctId":"NCT02578459","phase":"NA","title":"A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain","status":"WITHDRAWN","sponsor":"Flowonix Medical","startDate":"2016-04","conditions":"Pain Management, Cancer Pain","enrollment":""},{"nctId":"NCT01943435","phase":"NA","title":"Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)","status":"COMPLETED","sponsor":"Michael Schneider, DC, PhD","startDate":"2013-11-20","conditions":"Lumbar Spinal Stenosis","enrollment":259},{"nctId":"NCT00401258","phase":"PHASE4","title":"An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2006-11","conditions":"Irritable Bowel Syndrome","enrollment":15},{"nctId":"NCT02208778","phase":"PHASE4","title":"Imaging Pain Relief in Osteoarthritis","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2014-12","conditions":"Osteoarthritis, Chronic Pain","enrollment":77},{"nctId":"NCT00849901","phase":"PHASE3","title":"A Study in the Treatment of Children and Adolescents With Major Depressive Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-03","conditions":"Major Depressive Disorder","enrollment":337},{"nctId":"NCT00360724","phase":"PHASE4","title":"Duloxetine for Chronic Depression: a Double-blind Study","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2006-08","conditions":"Dysthymic Disorder, Depressive Disorder NOS","enrollment":65},{"nctId":"NCT00607789","phase":"PHASE4","title":"Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2006-10","conditions":"Binge Eating, Depression","enrollment":40},{"nctId":"NCT00118430","phase":"PHASE4","title":"Stepped Care for Depression and Musculoskeletal Pain","status":"COMPLETED","sponsor":"Indiana University","startDate":"2004-09","conditions":"Pain, Depression","enrollment":500},{"nctId":"NCT01944657","phase":"NA","title":"Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study","status":"WITHDRAWN","sponsor":"Sheppard Pratt Health System","startDate":"2013-09","conditions":"1. Major Depressive Disorder","enrollment":""},{"nctId":"NCT00599911","phase":"PHASE2","title":"Dose-finding Study With Lu AA24530 in Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-10","conditions":"Major Depressive Disorder","enrollment":652},{"nctId":"NCT02934035","phase":"","title":"Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2016-09","conditions":"Major Depressive Disorder","enrollment":10000},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT01564862","phase":"PHASE2","title":"Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-04","conditions":"Depressive Disorder, Major","enrollment":602},{"nctId":"NCT01852383","phase":"PHASE4","title":"Duloxetine Treatment in Elderly With Dysthymia","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2006-01","conditions":"Depression, Dysthymic Disorder","enrollment":30},{"nctId":"NCT00672620","phase":"PHASE3","title":"Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-04","conditions":"Major Depressive Disorder","enrollment":611},{"nctId":"NCT01153009","phase":"PHASE3","title":"Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-06","conditions":"Depressive Disorder, Major","enrollment":614},{"nctId":"NCT00730691","phase":"PHASE3","title":"Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-06","conditions":"Generalized Anxiety Disorder","enrollment":781},{"nctId":"NCT01028352","phase":"NA","title":"Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2008-10","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT01896349","phase":"NA","title":"Interpersonal Psychotherapy for Treatment Resistant Depression","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2013-04","conditions":"Treatment Resistant Depression","enrollment":74},{"nctId":"NCT00177671","phase":"PHASE4","title":"Antidepressant Medication Plus Donepezil for Treating Late-life Depression","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-12","conditions":"Depression, Dementia","enrollment":220},{"nctId":"NCT01089556","phase":"PHASE3","title":"A Study in Painful Diabetic Neuropathy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-03","conditions":"Diabetic Neuropathy, Painful","enrollment":811},{"nctId":"NCT01764867","phase":"PHASE4","title":"Algorithm Guided Treatment Strategies for Major Depressive Disorder","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2012-06","conditions":"Major Depressive Disorder","enrollment":1080},{"nctId":"NCT01018680","phase":"PHASE3","title":"A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-11","conditions":"Osteoarthritis Knee Pain","enrollment":524},{"nctId":"NCT00849693","phase":"PHASE3","title":"A Study in the Treatment of Children and Adolescents With Major Depressive Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-03","conditions":"Major Depressive Disorder","enrollment":463},{"nctId":"NCT00810069","phase":"PHASE4","title":"Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-11","conditions":"Major Depressive Disorder","enrollment":840},{"nctId":"NCT00945945","phase":"PHASE3","title":"A Study of Duloxetine in Patients With Osteoarthritis Knee Pain","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-07","conditions":"Osteoarthritis Knee Pain","enrollment":424},{"nctId":"NCT01268631","phase":"NA","title":"Mechanism-based Choice of Therapy: Can Treatments Success in Fibromyalgia Patients be Coupled to Psychophysical Pain Modulation Profile?","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2011-01","conditions":"Fibromyalgia","enrollment":150},{"nctId":"NCT00658931","phase":"PHASE4","title":"Cymbalta for Depression as a Complication of Bereavement","status":"UNKNOWN","sponsor":"Jefferson Clinic, P.C.","startDate":"2008-04","conditions":"Depression, Bereavement","enrollment":20},{"nctId":"NCT00561509","phase":"","title":"Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-11","conditions":"Major Depressive Disorder","enrollment":1626},{"nctId":"NCT00494377","phase":"PHASE4","title":"Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-02","conditions":"Depression","enrollment":940}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":["Teva Pharmaceuticals","Mylan Pharmaceuticals","Apotex Inc."],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":59,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Drug treatment with Cymbalta","genericName":"Drug treatment with Cymbalta","companyName":"Jefferson Clinic, P.C.","companyId":"jefferson-clinic-p-c","modality":"Small molecule","firstApprovalDate":"2004","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}